real-time news and commentary for investors
Friday, Sep 7
2012, 10:50 AM
Sarepta Pharmaceuticals (SRPT -5.3%) continues its decline today on the back of news earlier...
Sarepta Pharmaceuticals (SRPT -5.3%) continues its decline today on the back of news earlier this week that it had entered into an at-the-market equity offering sales agreement with Citadel Securities. It's all relative however, when you consider that the stock has been on a tear recently, gaining over 300% just since mid-July after releasing its 36-week data from their current phase IIb extension study of Eteplirsen, its potential treatment for Duchenne Muscular Dystrophy.